Spectral AI announced a 30% increase in its patent portfolio that strengthens and protects its proprietary, AI-driven DeepView System wound assessment platform. Total patents granted to the Company increased to 26 through July 8, 2024 from 20 at December 31, 2023, consisting of 12 U.S. and 14 international patents. These patents cover various aspects of the Company’s DeepView System platform. The Company continues to protect its data and processes with an additional 38 pending patent applications worldwide, consisting of seven pending U.S. patents and 31 pending international patents. The patents encompass nine distinct patent families.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDAI:
- Spectral AI Announces Total U.S. and International Patent Portfolio Now Stands at 26 Granted Patents and 38 Pending Applications in Support of its AI-Driven DeepView System
- Spectral adds three new clinical trial sites to expedite ED patient enrollment
- Spectral AI Adds Three New Clinical Trial Sites To Expedite Emergency Department Patient Enrollment
- Spectral AI initiated with a Buy at H.C. Wainwright
- Spectral AI Tackles Market Manipulation Concerns